The global HIV drugs market is set to gain traction from the increasing development of antiretroviral therapy to make it a first long-acting injectable formulation and a long-acting suppression (ATLAS). Physicians often anticipate that the ATLAS regimen can efficiently improve the compliance rates and can be made available in the once-a-month dosage form. In January 2021, for instance, Evergreen Health bagged the U.S. FDA approval for Cabenuva. It is the first complete and injectable regimen for HIV-1 infected adults that can be registered once every month. As per a published report by Fortune Business Insights™, titled, “HIV Drugs Market, 2021-2028,” the market stood at USD 28.79 billion in 2020. It is projected to grow from USD 30.46 billion in 2021 to USD 45.58 billion in 2028 at a CAGR of 5.9% in the forecast period.
Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/hiv-aids-drugs-market-101115
COVID-19 Pandemic: Declining Number of New Patient Prescriptions to Hamper Growth
The COVID-19 pandemic has severely affected the import and export activities of healthcare products worldwide on account of nationwide lockdowns and disturbances in supply chains. Besides, the reduced number of new patient prescriptions in highly COVID-impacted areas has further lowered the demand for antibiotic and antiretroviral HIV drugs. We are providing elaborate reports to help you find the best solution to enhance your businesses amid the pandemic.
To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/industry-reports/hiv-aids-drugs-market-101115
Segments–
Non-nucleoside Reverse Transcriptase Inhibitors Segment Held 5.6% in 2020: Fortune Business Insights™
Based on the distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others. By the drug class, it is divided into combination HIV medicines, integrase inhibitors, non-nucleoside reverse transcriptase inhibitors (NRTIs), and others. Out of these, the NRTIs segment generated 5.6% in terms of the HIV drugs market share in 2020. This is attributable to the reduced demand for this drug class, unlike for those with innovative formulations.
Report Coverage-
The research report offers an in-depth assessment of various customers’ journeys related to the market, regions, and segments. The analysis takes a closer look at their crucial pain points across numerous customer touch points. The business intelligence and consultation solutions would aid interested stakeholders, such as chief experience officers to define customer experience maps catered to their requirements. They can refine customer experience and engagement with their own brands of HIV drugs.
Speak To Our Analyst: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/hiv-aids-drugs-market-101115
Drivers & Restraints-
Increasing Number of New Product Launches to Augment Growth
The rising emphasis on R&D activities in the field of HIV drugs is expected to result in the rising drug innovations worldwide. Several reputed companies, such as Boehringer Ingelheim International GmbH, ViiV Healthcare, and Gilead Sciences are engaging in investment initiatives to compete in the market. Some of the others are participating in new product launches and collaborations. In September 2019, for instance, Merck Sharp & Dohme Corp. won the U.S. FDA approval for DELSTRIGO and PIFELTRO combination drugs. These will be used for the treatment of people living with HIV-1. However, many people suffering from this disease across the globe do not have access to timely treatment. It may obstruct the market growth in the near future.
Regional Insights-
Rising Prevalence of HIV in the U.S. to Help North America Dominate
Geographically, North America is anticipated to remain at the forefront throughout the forthcoming years because of the rising prevalence of HIV infections among the U.S. populations. As per the Centers for Disease Control (CDC), in 2018, more than 1.2 million individuals were suffering from this disorder. The region procured USD 20.27 billion in 2020 in terms of revenue in this market.
Moreover, Europe is likely to be the second-largest market backed by the presence of a large number of renowned HIV drug manufacturers in the region. Besides, these companies are constantly engaging in partnerships and collaborations to improve their footprint. In Asia Pacific, on the other hand, the surging population in India and China would aid the demand for HIV drugs in the upcoming years.
Quick Buy – HIV Drugs Market Research Report:
https://www.fortunebusinessinsights.com/checkout-page/101115
Competitive Landscape-
Key Players Focus on Gaining Fast-track Approvals to Intensify Competition
Prominent manufacturers of these drugs present in the global market are striving persistently to conduct extensive R&D activities to introduce new products. A few others are also aiming to gain fast-track approvals from regulatory bodies to market and distribute their drugs. Below is one of the industry developments:
- July 2020: Rukobia (fostemsavir), a unique antiretroviral medication received the U.S. FDA approval for its usage in adults suffering from HIV who have previously undergone various treatments that could not successfully treat their conditions.
A list of renowned vendors of HIV drugs operating in the global market:
- ViiV Healthcare (Research Triangle Park, U.S.)
- Gilead Sciences, Inc. (Foster City, U.S.)
- GlaxoSmithKline plc (Brentford, U.K.)
- Merck Sharp & Dohme Corp. (Kenilworth, France)
- Bristol-Myers Squibb Company (New York City, U.S.)
- Janssen Pharmaceuticals, Inc. (Johnson & Johnson) (Beerse, Belgium)
- Boehringer Ingelheim International GmbH (Ingelheim am Rhein, Germany)
- AbbVie Inc. (North Chicago, U.S.)
- Genentech, Inc. (F. Hoffmann-La Roche AG) (South San Francisco, U.S.)
- Mylan N.V. (Canonsburg, U.S.)
- Other Prominent Players
Table Of Contents :
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Epidemiology of HIV/AIDS, By Key Countries/Regions, 2020
- Regulatory Scenario by Key Countries
- Pipeline Analysis
- Overview of Current Advances in R&D for HIV Drugs
- Key Strategies Employed by Market Leaders
- Key Industry Developments
- New Product Launches
- Global HIV Drugs Market Analysis, Insights and Forecast, 2017-2028
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Drug Class
- Integrase Inhibitors
- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combination HIV Medicines
- Others
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Rest of the World
- North America HIV Drugs Market Analysis, Insights and Forecast, 2017-2028
- Key Findings / Summary
- Market Analysis – By Drug Class
- Integrase Inhibitors
- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combination HIV Medicines
- Others
- Market Analysis – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Market Analysis – By Country
- U.S.
- By Drug Class
- Integrase Inhibitors
- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combination HIV Medicines
- Others
-
-
- Canada
-
- By Drug Class
- Integrase Inhibitors
- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combination HIV Medicines
- Others
- Europe HIV Drugs Market Analysis, Insights and Forecast, 2017-2028
- Key Findings / Summary
- Market Analysis – By Drug Class
- Integrase Inhibitors
- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combination HIV Medicines
- Others
- Market Analysis – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Market Analysis – By Country/ Sub-Region
- Germany
- By Drug Class
- Integrase Inhibitors
- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combination HIV Medicines
- Others
-
-
- France
-
- By Drug Class
- Integrase Inhibitors
- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combination HIV Medicines
- Others
-
-
- U.K.
-
- By Drug Class
- Integrase Inhibitors
- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combination HIV Medicines
- Others
-
-
- Italy
-
- By Drug Class
- Integrase Inhibitors
- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combination HIV Medicines
- Others
-
-
- Spain
-
- By Drug Class
- Integrase Inhibitors
- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combination HIV Medicines
- Others
-
-
- Netherlands
-
- By Drug Class
- Integrase Inhibitors
- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combination HIV Medicines
- Others
-
-
- Rest of Europe
-
- By Drug Class
- Integrase Inhibitors
- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combination HIV Medicines
- Others
Ask for Customization of this Report:
https://www.fortunebusinessinsights.com/enquiry/customization/hiv-aids-drugs-market-101115
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
LinkedIn: https://www.linkedin.com/company/fortune-business-insights
Facebook: https://www.facebook.com/FortuneBusinessInsightsPvtLtd
Read Press Release: https://www.fortunebusinessinsights.com/press-release/hiv-aids-drugs-market-9223